Contrasting Pluri (PLUR) and The Competition

Pluri (NASDAQ:PLUR) is one of 844 publicly-traded companies in the “Biotechnology” industry, but how does it contrast to its peers? We will compare Pluri to similar companies based on the strength of its earnings, analyst recommendations, institutional ownership, dividends, risk, profitability and valuation.

Analyst Ratings

This is a summary of recent ratings and price targets for Pluri and its peers, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pluri	1	0	0	0	1.00
Pluri Competitors	9874	15290	45646	1600	2.54

As a group, “Biotechnology” companies have a potential upside of 127.20%. Given Pluri’s peers stronger consensus rating and higher possible upside, analysts plainly believe Pluri has less favorable growth aspects than its peers.

Valuation and Earnings

This table compares Pluri and its peers revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Pluri	$1.02 million	-$23.82 million	-0.43
Pluri Competitors	$702.34 million	$9.48 million	-18.82

Pluri’s peers have higher revenue and earnings than Pluri. Pluri is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.

Profitability

This table compares Pluri and its peers’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Pluri	-2,344.59%	N/A	-82.71%
Pluri Competitors	-12,323.33%	-195.91%	-30.60%

Institutional & Insider Ownership

16.6% of Pluri shares are owned by institutional investors. Comparatively, 47.8% of shares of all “Biotechnology” companies are owned by institutional investors. 43.2% of Pluri shares are owned by company insiders. Comparatively, 13.1% of shares of all “Biotechnology” companies are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Risk & Volatility

Pluri has a beta of 0.64, meaning that its share price is 36% less volatile than the S&P 500. Comparatively, Pluri’s peers have a beta of -1.84, meaning that their average share price is 284% less volatile than the S&P 500.

Summary

Pluri peers beat Pluri on 8 of the 13 factors compared.

Pluri Company Profile

Pluri Inc. is a biotechnology company developing cell-based products and technologies for applications in human health, food production and other industries. The company’s platform uses three-dimensional cell expansion technology designed to grow cells at commercial scale without genetic modification. Pluri’s health-related research has historically focused on placenta-derived, off-the-shelf cell therapies, including its PLX product candidates, which have been investigated for potential use in conditions involving inflammation, tissue damage and impaired blood flow.